Key Highlights

● The S&P 500 health care sector climbed to a record high on Thursday.

● Johnson & Johnson led the sector, trading at $267.61, and Amgen rose to $447.28.

● Quest Diagnostics raised its full-year earnings guidance to $11.25 to $11.35 a share.

● Biohaven soared after the FDA accepted its resubmitted application for troriluzole.

Health care investors had to look past a dramatic collapse on Thursday. Most of them did.

The S&P 500 health care sector climbed to a record high on Thursday, October 22, even as Moderna (NASDAQ:MRNA) was the worst performer in the entire S&P 500. Johnson & Johnson (NYSE:JNJ) led the way, climbing to trade at $267.61 with no company-specific news.

The sector's strength contrasted with the broader market. The S&P 500 fell 93.74 points to 7,663.43, its worst day since July, and the Nasdaq Composite tumbled 694 points to 26,008.86.

The defensive bid

Johnson & Johnson's gain reflected a broad rotation into defensive stocks as investors fled technology. Amgen (NASDAQ:AMGN) rose to trade at $447.28, also without company-specific news.

Health care companies tend to see steady demand regardless of the economic cycle, which makes the sector a common refuge when riskier stocks sell off. Thursday's flight came after Meta Platforms reported negative free cash flow and about $825 billion in spending commitments, and after Lam Research cited supply constraints.

"People are running away from tech," one strategist said.

Earnings beats help

Several health care companies posted solid results. Quest Diagnostics (NYSE:DGX) reported revenue of $3.1 billion against forecasts of $3.05 billion and earnings of $3.00 a share against $2.87 expected. It raised its full-year earnings guidance to $11.25 to $11.35 a share.

Medpace also beat expectations, according to market reports. Healthcare Services Group rallied after adjusted earnings of $0.36 a share topped estimates of $0.24.

Biohaven soared after the FDA accepted its resubmitted application for troriluzole in spinocerebellar ataxia. Lycia Therapeutics priced an upsized initial public offering at $18.00 a share, raising about $317.5 million, ahead of its Friday debut.

Moderna's collapse

The sector's record came despite Moderna's slide. The stock plunged, trading at $202.63, after Phase 3 data for its melanoma vaccine, developed with Merck (NYSE:MRK), appeared before its scheduled presentation and was reportedly leaked. At one point it was down even more steeply, and about $24 billion in market value was erased.

Analysts largely described the data as solid. One called it "solid data" and a "sell the news" event. The stock had risen more than sixfold this year before Thursday. Merck slipped to $147.24.

Because Moderna is far smaller than giants like Johnson & Johnson, its drop weighed less on the sector than the gains in larger names lifted it.

Part of a wider rotation

Health care was not alone. Consumer staples had their best day since April 2025 and also hit a record, led by Procter & Gamble. Utilities, financials and real estate gained.

About two of every three S&P 500 stocks rose, according to market data, and the equal-weight S&P 500 rose. Treasuries rallied, pushing the 10-year yield back below a closely watched threshold for the first time since September 22.

The Dow Jones Industrial Average, which includes Johnson & Johnson and Amgen, edged up 11.89 points to 52,867.98.

Melanoma Data and Big Tech Ahead

Moderna and Merck present full melanoma data at the ESMO conference in Madrid on Saturday, which could move both stocks on Monday. Investors will also watch whether the defensive rotation into health care continues as big tech reports next week, with Microsoft and Alphabet on October 28 and Amazon on October 29, alongside the Federal Reserve's decision.